| 1.39 -0.01 (-0.71%) | 12-05 10:05 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.79  |
1-year : | 2.1 |
| Resists | First : | 1.53 |
Second : | 1.79 |
| Pivot price | 1.37  |
|||
| Supports | First : | 1.33 |
Second : | 1.21 |
| MAs | MA(5) : | 1.37 |
MA(20) : | 1.36 |
| MA(100) : | 1.51 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 61.8 |
D(3) : | 56.2 |
| RSI | RSI(14): 48.5 |
|||
| 52-week | High : | 3.32 | Low : | 1 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ZNTL ] has closed below upper band by 36.6%. Bollinger Bands are 51.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.41 - 1.42 | 1.42 - 1.43 |
| Low: | 1.34 - 1.35 | 1.35 - 1.36 |
| Close: | 1.39 - 1.4 | 1.4 - 1.41 |
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Wed, 03 Dec 2025
We're Keeping An Eye On Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate - Yahoo Finance
Tue, 18 Nov 2025
Zentalis Pharmaceuticals: Hanging On For One Last Shot At PROC Approval (ZNTL) - Seeking Alpha
Wed, 12 Nov 2025
ZNTL Stock Update: Morgan Stanley Lowers Price Target by 50% | Z - GuruFocus
Tue, 11 Nov 2025
Zentalis Pharmaceuticals Reports Q3 2025 Financial Results - TipRanks
Mon, 10 Nov 2025
Zentalis Pharmaceuticals Reports Q3 2025 Financial Results - TipRanks
Tue, 04 Nov 2025
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 72 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 13.5 (%) |
| Held by Institutions | 72.5 (%) |
| Shares Short | 5,080 (K) |
| Shares Short P.Month | 4,940 (K) |
| EPS | -2.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.5 |
| Profit Margin | 0 % |
| Operating Margin | -567.8 % |
| Return on Assets (ttm) | -24.6 % |
| Return on Equity (ttm) | -49.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.37 |
| Sales Per Share | 0.37 |
| EBITDA (p.s.) | -2.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -134 (M) |
| Levered Free Cash Flow | -63 (M) |
| PE Ratio | -0.68 |
| PEG Ratio | 0 |
| Price to Book value | 0.39 |
| Price to Sales | 3.74 |
| Price to Cash Flow | -0.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|